Onesource Specialty Pharma’s partner Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic. The company serves as the CDMO partner on this program, providing scale-up and manufacturing support. The partnership is designed to ensure reliable and scalable commercial supply from the company’s US-FDA approved flagship manufacturing facility in Bengaluru.
OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.
